Lilly Endowment Inc, an insider of Eli Lilly and Co (LLY), sold 93,557,719 shares on November 10, 2025, at a price of $987.18 per share. The total value of this transaction amounted to $92,358.59 million.
Following this sale, Lilly Endowment Inc retains an equal number of shares in the company. Eli Lilly, a major player in the pharmaceuticals industry, is headquartered in Indianapolis, Indiana, and employs approximately 47,000 full-time staff. The company specializes in the discovery, development, manufacture, and sale of pharmaceutical products, including treatments for cardiometabolic health, oncology, immunology, and neuroscience.
As of November 13, 2025, Eli Lilly's market capitalization stands at $962.2 billion, with a P/E ratio of 52.26 and an EPS of 20.45. The company has a dividend yield of 59.0%. Upcoming earnings are projected for April 28, 2026, with an estimated EPS of $7.07 and revenue of $17.2 billion, followed by another report on August 4, 2026, with an EPS estimate of $7.70 and revenue expectations of $17.9 billion.
Insider transactions, such as this sale, are reported to the SEC and provide transparency regarding insider sentiment. However, these transactions should not be the sole factor in investment decisions, as they can stem from various personal or regulatory motivations. Investors are encouraged to evaluate patterns of insider activity over time and across multiple insiders to gain a comprehensive view.